Madison-based Stratatech Corp. announced Monday the successful completion of a clinical trial of its StrataGraft human skin substitute. The company said the trial showed StrataGraft performed comparable to the current standard of care.
The clinical trial was designed to evaluate the safety and effectiveness of StrataGraft in patients with major skin trauma that required temporary skin replacement before “autografting” — the transplantation of live skin tissue from one part of a patient’s body to another.
….The University of Wisconsin-Madison’s Michael J. Schurr was the trial’s principal clinical investigator.